Spectrum Asset Management Inc. NB CA maintained its position in Johnson & Johnson (NYSE:JNJ) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,072 shares of the company’s stock at the close of the 2nd quarter. Spectrum Asset Management Inc. NB CA’s holdings in Johnson & Johnson were worth $274,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently added to or reduced their stakes in JNJ. Lenox Wealth Advisors Inc. lifted its position in shares of Johnson & Johnson by 0.6% during the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after acquiring an additional 5 shares during the period. Harel Insurance Investments & Financial Services Ltd. lifted its position in shares of Johnson & Johnson by 241.0% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock valued at $149,000 after acquiring an additional 841 shares during the period. Ullmann Financial Group Inc. bought a new stake in shares of Johnson & Johnson during the 1st quarter valued at $186,000. Taylor Wealth Management Partners raised its holdings in shares of Johnson & Johnson by 19.8% during the 1st quarter. Taylor Wealth Management Partners now owns 1,510 shares of the company’s stock worth $188,000 after buying an additional 250 shares in the last quarter. Finally, Puplava Financial Services Inc. acquired a new position in shares of Johnson & Johnson during the 2nd quarter worth $202,000. Hedge funds and other institutional investors own 66.06% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This report was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.watchlistnews.com/spectrum-asset-management-inc-nb-ca-has-274000-position-in-johnson-johnson-jnj/1677142.html.

Shares of Johnson & Johnson (JNJ) opened at $140.08 on Friday. The company has a market cap of $375.92 billion, a price-to-earnings ratio of 19.60, a PEG ratio of 2.84 and a beta of 0.82. The company has a quick ratio of 1.01, a current ratio of 1.34 and a debt-to-equity ratio of 0.38.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.80 by $0.10. The company had revenue of $19.65 billion during the quarter, compared to analysts’ expectations of $19.29 billion. Johnson & Johnson had a return on equity of 27.68% and a net margin of 21.28%. The business’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.68 earnings per share. equities research analysts anticipate that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be paid a $0.84 dividend. The ex-dividend date is Monday, November 27th. This represents a $3.36 annualized dividend and a dividend yield of 2.40%. Johnson & Johnson’s payout ratio is 58.33%.

A number of equities analysts have recently commented on the company. Citigroup Inc boosted their price target on Johnson & Johnson from $140.00 to $149.00 and gave the stock a “buy” rating in a report on Monday, October 23rd. Vetr raised Johnson & Johnson from a “sell” rating to a “hold” rating and set a $137.71 price target for the company in a report on Monday, October 30th. Leerink Swann reissued an “outperform” rating and set a $165.00 price target (up previously from $150.00) on shares of Johnson & Johnson in a report on Wednesday, October 18th. Royal Bank Of Canada boosted their price target on Johnson & Johnson from $144.00 to $147.00 and gave the stock an “outperform” rating in a report on Wednesday, October 18th. Finally, Stifel Nicolaus boosted their price target on Johnson & Johnson from $140.00 to $142.00 and gave the stock a “hold” rating in a report on Wednesday, October 18th. Four investment analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $143.70.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.